Citations

Clear

959 citation(s) found for "Service, F J".

Phylogenetics and biogeography of the two‐wing flyingfish (Exocoetidae: Exocoetus)
Lewallen, Eric A. , Bohonak, Andrew J. , Bonin, Carolina A. , Wijnen, André J. van , Lovejoy, Nathan R. , van Wijnen, Andre J, Pitman, Robert L. , van Wijnen, Andre J

Mayo Clinic

Ecology and Evolution | February 13, 2017 | Volume: 7 | Issue: 6 | Pages: 1751-1761

10.1002/ece3.2786 | PMID 28331585 Get It

AbstractTwo‐wing flyingfish (Exocoetus spp.) are widely distributed, epipelagic, mid‐trophic organisms that feed on zooplankton and are preyed upon by numerous predators (e.g., tunas, dolphinfish, tropical seabirds), yet an understanding of their speciation and systematics is lacking. As a model of epipelagic fish speciation and to investigate mechanisms that increase biodiversity, we studied the phylogeny and biogeography of Exocoetus, a highly abundant holoepipelagic fish taxon of the tropical open ocean. Morphological and molecular data were used to evaluate the phylogenetic relationships, species boundaries, and biogeographic patterns of the five putative Exocoetus species. We show that the most widespread species (E. volitans) is sister to all other species, and we find no evidence for cryptic species in this taxon. Sister relationship between E. monocirrhus (Indo‐Pacific) and E. obtusirostris (Atlantic) indicates the Isthmus of Panama and/or Benguela Barrier may have played a role in their divergence via allopatric speciation. The sister species E. peruvianus and E. gibbosus are found in different regions of the Pacific Ocean; however, our molecular results do not show a clear distinction between these species, indicating recent divergence or ongoing gene flow. Overall, our phylogeny reveals that the most spatially restricted species are more recently derived, suggesting that allopatric barriers may drive speciation, but subsequent dispersal and range expansion may affect the distributions of species.
Feasibility, Benefits, and Limitations of a Penicillin Allergy Skin Testing Service
Narayanan, Prasanna P., Jeffres, Meghan N.

Mayo Clinic

Annals of Pharmacotherapy | February 3, 2017 | Volume: 51 | Issue: 6 | Pages: 504-510

10.1177/1060028017690854 | PMID 28152605 Get It

Objective: To critically examine the feasibility, benefits, and limitations of an inpatient penicillin skin testing service and how pharmacists can be utilized. Data Sources: A PubMed search was performed from July 2016 through September 2016 using the following search terms: penicillin skin testing, penicillin allergy, β-lactam allergy. Additional references were identified from a review of literature citations. Study Selection and Data Extraction: All English-language studies assessing the use of penicillin skin testing as well as management and clinical outcomes of patients with a β-lactam allergy were evaluated. Data Synthesis: The prevalence of people self-identifying as penicillin allergic ranges from 10% to 20% in the United States. Being improperly labeled as penicillin allergic is associated with higher health care costs, worse clinical outcomes, and an increased prevalence of multidrug-resistant infections. Penicillin skin testing can be a tool used to clarify penicillin allergies and has been demonstrated to be a successful addition to antimicrobial stewardship programs in multiple health care settings. Prior to implementing a penicillin skin testing service, institutions will need to perform a feasibility analysis of who will supply labor and accept the financial burden as well as identify if the positive benefits of a penicillin skin testing service overcome the limitations of this diagnostic test. Conclusion: We conclude that institutions with high percentages of patients receiving non–β-lactams because of penicillin allergy labels would likely benefit the most from a penicillin skin testing service.
Impact of a Primary Inpatient Electrophysiology Service on Cardiovascular Implantable Electronic Device Infections in a Tertiary Care Hospital
Anderson, Brenda, Linderbaum, Jane A. , Ziel, Thomas De, Li, Zhuo, Cha, Yong‐Mei , Loomis, Erica, Espinosa, Raúl E. , Friedman, Paul A. , Greason, Kevin L. , Schiller, Henry J., Virk, Abinash , Wilson, Walter R., Steckelberg, James M., Tan, Eugene M. , Nagpal, Avish , DeSimone, Daniel C. , Sohail, M. Rizwan , Baddour, Larry M.

Mayo Clinic

Open Forum Infectious Diseases | February 2, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.810 Get It

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Merryman, Reid W. , Zinzani, Pier Luigi , Carlo‐Stella, Carmelo , Ansell, Stephen M. , Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad , Houot, Roch, Marchand, Tony , Dhédin, Nathalie , Lescaut, W., Thiebaut‐Bertrand, Anne , François, Sylvie, Stamatoullas‐Bastard, Aspasia, Rohrlich, Pierre-Simon, Wallet, Hélène Labussière, Castagna, Luca , Santoro, Armando , Bachanová, Veronika , Bresler, Scott C., Kim, Harim , Pesek, Emily, Chammas, Marie J, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J. , Armand, Philippe , Kim, Haesook T. , Houot, Roch , Rohrlich, Pierre‐Simon , Bresler, Scott C. , Srivastava, Amitabh , Reynolds, Carol, Antin, Joseph H. , Ritz, Jerome , Bachanova, Veronika , Zinzani, Pier Luigi , Santoro, Armando , Castagna, Luca , Carlo-Stella, Carmelo , Merryman, Reid W

Mayo Clinic

Blood | January 10, 2017 | Volume: 129 | Issue: 10 | Pages: 1380-1388

10.1182/blood-2016-09-738385 | PMID 28073785 Get It

Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction
Kristensen, Søren Lund , Mogensen, Ulrik M. , Jhund, Pardeep S. , Petrie, Mark C. , Preiss, David , Win, Sithu , Køber, Lars , McKelvie, Robert S. , Zile, Michael R. , Anand, Inder S. , Komajda, Michel , Gottdiener, John S. , Carson, Peter E., McMurray, John J.V. , Felker, G. Michael , Kristensen, Søren L, Zile, Michael R , Anand, Inder S , McMurray, John J V , Petrie, Mark C , Jhund, Pardeep S , Køber, Lars

Mayo Clinic

Circulation | January 5, 2017 | Volume: 135 | Issue: 8 | Pages: 724-735

10.1161/circulationaha.116.024593 | PMID 28052977 Get It

Background: In patients with heart failure and preserved ejection fraction, little is known about the characteristics of, and outcomes in, those with and without diabetes mellitus. Methods: We examined clinical and echocardiographic characteristics and outcomes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) according to history of diabetes mellitus. Cox regression models were used to estimate hazard ratios for cardiovascular outcomes adjusted for known predictors, including age, sex, natriuretic peptides, and comorbidity. Echocardiographic data were available in 745 patients and were additionally adjusted for in supplementary analyses. Results: Overall, 1134 of 4128 patients (27%) had diabetes mellitus. Compared with those without diabetes mellitus, they were more likely to have a history of myocardial infarction (28% versus 22%), higher body mass index (31 versus 29 kg/m 2 ), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL; all P <0.01), more signs of congestion, but no significant difference in left ventricular ejection fraction. Patients with diabetes mellitus had a greater left ventricular mass and left atrial area than patients without diabetes mellitus. Doppler E-wave velocity (86 versus 76 cm/s; P <0.0001) and the E/e’ ratio (11.7 versus 10.4; P =0.010) were higher in patients with diabetes mellitus. Over a median follow-up of 4.1 years, cardiovascular death or heart failure hospitalization occurred in 34% of patients with diabetes mellitus versus 22% of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% confidence interval, 1.49–2.05), and 28% versus 19% of patients with and without diabetes mellitus died (adjusted hazard ratio, 1.59; confidence interval, 1.33–1.91). Conclusions: In heart failure with preserved ejection fraction, patients with diabetes mellitus have more signs of congestion, worse quality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis. They also display greater structural and functional echocardiographic abnormalities. Further investigation is needed to determine the mediators of the adverse impact of diabetes mellitus on outcomes in heart failure with preserved ejection fraction and whether they are modifiable. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00095238.
The cobas® 6800/8800 System: a new era of automation in molecular diagnostics
Cobb, Bryan, Simon, Christian O., Body, Barbara A., Mitchell, P. Shawn, Reisch, Nataša, Stevens, Wendy , Carmona, Sergio , Katz, Louis N., Will, Stephen, Liesenfeld, Oliver , Stramer, Susan L. , Katz, Louis

Mayo Clinic

Expert Review of Molecular Diagnostics | January 3, 2017 | Volume: 17 | Issue: 2 | Pages: 167-180

10.1080/14737159.2017.1275962 | PMID 28043179 Get It

Elevated rates of memory impairment in military service-members and veterans with posttraumatic stress disorder
Stricker, Nikki H. , Lippa, Sara M. , Green, Deborah L., McGlynn, Susan M., Grande, Laura, McGlinchey, Regina E. , Milberg, William P , Stricker, Nikki H

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | December 18, 2016 | Volume: 39 | Issue: 8 | Pages: 768-785

10.1080/13803395.2016.1264575 | PMID 27976973 Get It

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Grever, Michael R. , Andritsos, Leslie A. , Call, Timothy G. , Catovsky, Daniel , Dearden, Claire , Demeter, Judit , Else, Monica , Forconi, Francesco , Gozzetti, Alessandro , Ho, Anthony D. , Johnston, James B. , Jones, Jeffrey A. , Juliusson, Gunnar , Kraut, Eric H., Kreitman, Robert J. , Larratt, Loree, Lauria, Francesco, Lozanski, Gerard , Montserrat, Emili , Park, Jae H. , Polliack, Aaron, Quest, Graeme, Rai, Kanti R., Robak, Tadeusz , Saven, Alan, Seymour, John F. , Tallman, Martin S. , Tam, Constantine S. , Tiacci, Enrico , Zinzani, Pier Luigi , Falini, Brunangelo , Abdel‐Wahab, Omar , Banerji, Versha , Barrientos, Jacqueline C. , Blachly, James S. , Parikh, Sameer A. , Rai, Kanti R., Ravandi, Farhad , Robak, Tadeusz , Tadmor, Tamar , Troussard, Xavier , Zent, Clive S. , Zenz, Thorsten , Tam, Constantine S , Zinzani, Pier Luigi , Falini, Brunangelo , Gozzetti, Alessandro , Forconi, Francesco

Mayo Clinic

Blood | December 1, 2016 | Volume: 129 | Issue: 5 | Pages: 553-560

10.1182/blood-2016-01-689422 | PMID 27903528 Get It

AbstractHairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.